These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29655797)

  • 1. Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice.
    Vartiainen V; Raula J; Bimbo LM; Viinamäki J; Backman JT; Ugur N; Kauppinen E; Sutinen E; Joensuu E; Koli K; Myllärniemi M
    Int J Pharm; 2018 Jun; 544(1):121-128. PubMed ID: 29655797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aerosolization, Drug Permeation and Cellular Interaction of Dry Powder Pulmonary Formulations of Corticosteroids with Hydroxypropyl-β-Cyclodextrin as a Solubilizer.
    Vartiainen V; Bimbo LM; Hirvonen J; Kauppinen EI; Raula J
    Pharm Res; 2017 Jan; 34(1):25-35. PubMed ID: 27604893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
    Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
    J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
    Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
    Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug permeation and cellular interaction of amino acid-coated drug combination powders for pulmonary delivery.
    Vartiainen V; Bimbo LM; Hirvonen J; Kauppinen EI; Raula J
    Int J Pharm; 2016 May; 504(1-2):89-97. PubMed ID: 27034001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
    Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
    Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an Excipient-Free Peptide Dry Powder Inhalation for the Treatment of Pulmonary Fibrosis.
    Zhang Y; MacKenzie B; Koleng JJ; Maier E; Warnken ZN; Williams RO
    Mol Pharm; 2020 Feb; 17(2):632-644. PubMed ID: 31913640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
    Eedara BB; Tucker IG; Das SC
    Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
    Karimi K; Katona G; Csóka I; Ambrus R
    J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
    Rawal T; Parmar R; Tyagi RK; Butani S
    Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-steroidal anti-inflammatory drug for pulmonary administration: design and investigation of ketoprofen lysinate fine dry powders.
    Stigliani M; Aquino RP; Del Gaudio P; Mencherini T; Sansone F; Russo P
    Int J Pharm; 2013 May; 448(1):198-204. PubMed ID: 23528281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.
    Kawabata Y; Aoki Y; Matsui T; Yamamoto K; Sato H; Onoue S; Yamada S
    Eur J Pharm Biopharm; 2011 Jan; 77(1):178-81. PubMed ID: 21081161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of nicotine release from nicotine-loaded chitosan nanoparticles dry powder inhaler formulations via locomotor activity of C57BL/6 mice.
    Wang H; Holgate J; Bartlett S; Islam N
    Eur J Pharm Biopharm; 2020 Sep; 154():175-185. PubMed ID: 32682941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone morphogenetic protein-inducer tilorone identified by high-throughput screening is antifibrotic in vivo.
    Leppäranta O; Tikkanen JM; Bespalov MM; Koli K; Myllärniemi M
    Am J Respir Cell Mol Biol; 2013 Apr; 48(4):448-55. PubMed ID: 23258233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
    Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
    Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection.
    Arora S; Haghi M; Loo CY; Traini D; Young PM; Jain S
    Mol Pharm; 2015 Jun; 12(6):2001-9. PubMed ID: 25923171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Chemical Conjugation of l-Leucine to Chitosan on Dispersibility and Controlled Release of Drug from a Nanoparticulate Dry Powder Inhaler Formulation.
    Muhsin MD; George G; Beagley K; Ferro V; Wang H; Islam N
    Mol Pharm; 2016 May; 13(5):1455-66. PubMed ID: 26998555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
    Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
    Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
    Rawal T; Kremer L; Halloum I; Butani S
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.